People with HIV and comorbid substance use problems may be among those who benefit most from long-acting HIV antiretroviral treatment, but they are routinely excluded from Phase 3 clinical trials. Their inclusion would permit an examination of the clinical value of long-acting therapies for people with adherence problems and an exploration of syndemic interactions between HIV, mental health conditions, and substance use problems, which compound into a major challenge in the efforts to end the HIV epidemic.
Keyphrases
- mental health
- hiv positive
- antiretroviral therapy
- hiv infected
- human immunodeficiency virus
- hiv testing
- hiv aids
- hepatitis c virus
- men who have sex with men
- clinical trial
- hiv infected patients
- south africa
- mental illness
- randomized controlled trial
- metabolic syndrome
- skeletal muscle
- open label
- insulin resistance
- replacement therapy